An open-label phase I safety, pharmacokinetic and dosimetry study of 188Re-PTI-6D2 in patients with metastatic melanoma

Trial Profile

An open-label phase I safety, pharmacokinetic and dosimetry study of 188Re-PTI-6D2 in patients with metastatic melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2011

At a glance

  • Drugs PTI 188 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Feb 2011 Survival results will be presented at the 2011 American Society of Clinical Oncology Meeting, according to a Pain Therapeutics media release.
    • 23 Mar 2010 Positive efficacy results evaluating both phase I trials in patients with metastatic melanoma in Israel have been reported in a Pain Therapeutics media release.
    • 23 Jun 2008 Top-line results reported in a Pain Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top